These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 18000091)

  • 21. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
    Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
    Basolo F; Torregrossa L; Giannini R; Miccoli M; Lupi C; Sensi E; Berti P; Elisei R; Vitti P; Baggiani A; Miccoli P
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4197-205. PubMed ID: 20631031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
    Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
    Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
    Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
    Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
    Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
    Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
    Kim KH; Suh KS; Kang DW; Kang DY
    Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
    Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
    Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.